Natixis Cuts Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Natixis decreased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 75.2% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 5,456 shares of the biopharmaceutical company’s stock after selling 16,576 shares during the period. Natixis’ holdings in Regeneron Pharmaceuticals were worth $5,251,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Eudaimonia Advisors LLC grew its position in shares of Regeneron Pharmaceuticals by 1.2% in the fourth quarter. Eudaimonia Advisors LLC now owns 914 shares of the biopharmaceutical company’s stock valued at $803,000 after purchasing an additional 11 shares during the period. Team Hewins LLC grew its position in shares of Regeneron Pharmaceuticals by 2.5% in the first quarter. Team Hewins LLC now owns 451 shares of the biopharmaceutical company’s stock valued at $434,000 after purchasing an additional 11 shares during the period. Angeles Wealth Management LLC grew its position in shares of Regeneron Pharmaceuticals by 3.5% in the first quarter. Angeles Wealth Management LLC now owns 325 shares of the biopharmaceutical company’s stock valued at $313,000 after purchasing an additional 11 shares during the period. Drive Wealth Management LLC boosted its position in Regeneron Pharmaceuticals by 4.0% during the fourth quarter. Drive Wealth Management LLC now owns 311 shares of the biopharmaceutical company’s stock worth $273,000 after acquiring an additional 12 shares during the last quarter. Finally, MCF Advisors LLC boosted its position in Regeneron Pharmaceuticals by 50.0% during the fourth quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 12 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Up 0.8 %

Shares of Regeneron Pharmaceuticals stock opened at $1,073.22 on Friday. The company has a fifty day simple moving average of $1,031.92 and a 200-day simple moving average of $975.57. Regeneron Pharmaceuticals, Inc. has a 12-month low of $723.56 and a 12-month high of $1,106.16. The company has a current ratio of 5.27, a quick ratio of 4.51 and a debt-to-equity ratio of 0.10. The stock has a market cap of $118.26 billion, a price-to-earnings ratio of 31.44, a PEG ratio of 2.20 and a beta of 0.13.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share (EPS) for the quarter, missing the consensus estimate of $8.46 by ($0.49). Regeneron Pharmaceuticals had a net margin of 29.45% and a return on equity of 16.83%. The company had revenue of $3.15 billion during the quarter, compared to analyst estimates of $3.19 billion. On average, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.02 EPS for the current fiscal year.

Insider Activity

In other Regeneron Pharmaceuticals news, Director Michael S. Brown sold 1,172 shares of the firm’s stock in a transaction on Tuesday, May 28th. The shares were sold at an average price of $974.86, for a total transaction of $1,142,535.92. Following the transaction, the director now directly owns 1,382 shares of the company’s stock, valued at approximately $1,347,256.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $1,059.24, for a total transaction of $105,924.00. Following the transaction, the director now directly owns 17,882 shares of the company’s stock, valued at approximately $18,941,329.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Michael S. Brown sold 1,172 shares of the firm’s stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $974.86, for a total transaction of $1,142,535.92. Following the completion of the sale, the director now owns 1,382 shares of the company’s stock, valued at approximately $1,347,256.52. The disclosure for this sale can be found here. In the last quarter, insiders sold 65,074 shares of company stock worth $64,546,123. Corporate insiders own 7.48% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on REGN shares. Canaccord Genuity Group restated a “buy” rating and set a $1,152.00 price target on shares of Regeneron Pharmaceuticals in a research report on Thursday, June 27th. Barclays boosted their target price on shares of Regeneron Pharmaceuticals from $1,050.00 to $1,200.00 and gave the company an “overweight” rating in a report on Wednesday, July 10th. TD Cowen boosted their price target on shares of Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the company a “buy” rating in a research note on Tuesday. Evercore ISI initiated coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, May 14th. They issued an “outperform” rating and a $1,150.00 price target on the stock. Finally, StockNews.com downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, April 30th. One analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $1,074.95.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.